Table 2.
Results of pairwise and network meta-analysis for pain relief in different follow-ups
| At 1 st month | CS | -1.17 (-2.20 to -0.01) | -0.36 (-0.97 to 0.23) | -0.62 (-1.39 to 0.10) | -0.92 (-2.24 to 0.44) |
| -0.22 (-1.06 to 0.59) | BT | NA | NA | -1.40 (-2.18 to -0.60) | |
| -0.60 (-1.14 to -0.04) | -0.37 (-1.32 to 0.58) | AB | 0.27 (-0.75 to 1.34) | 0.18 (-1.13 to 1.51) | |
| -0.70 (-0.13 to -1.28) | -0.48 (-1.38 to 0.42) | -0.11 (-0.79 to 0.56) | PRP | 0.09 (-0.80 to 0.93) | |
| -1.04 (-1.78 to -0.34) | -0.83 (-1.54 to -0.05) | -0.44 (-1.24 to 0.33) | 0.32 (-1.05 to 0.39) | PL | |
| At 3 rd month | BT | NA | NA | 0.27 (-0.65 to 1.17) | -1.30 (-1.97 to -0.63) |
| -0.11 (0.99 to 0.82) | AB | 0.31 (-0.65 to 1.29) | -0.73 (-1.37 to -0.08) | -0.04 (-1.22 to 1.19) | |
| -0.10 (-1.02 to 0.84) | 0.01 (-0.68 to 0.69) | PRP | -0.52 (-1.34 to 0.33) | -0.03 (-1.12 to 1.13) | |
| -0.59 (-1.38 to 0.27) | -0.46 (-1.05 to 0.11) | -0.47 (-1.11 to 0.15) | CS | 0.04 (-1.76 to 1.80) | |
| -0.79 (-1.47 to -0.05) | -0.67 (-1.49 to 0.16) | -0.68 (-1.52 to 0.16) | -0.20 (-1.02 to 0.58) | PL | |
| At 6 th month | PRP | 0.18 (-1.14 to 1.47) | -0.27 (-1.41 to 0.82) | -1.91 (-2.91 to -0.91) | |
| -0.20 (-1.29 to 0.83) | PL | -0.13 (-1.45 to 1.07) | -0.48 (-2.26 to 1.34) | ||
| -0.54 (-1.36 to 0.26) | -0.35 (-1.44 to 0.78) | AB | -0.67 (-1.60 to 0.28) | ||
| -1.50 (-2.33 to -0.73) | -1.30 (-2.49 to -0.17) | -0.96 (-1.76 to -0.22) | CS |
Note: Treatments are ranked according to their SUCRA. The comparative therapeutic efficacies are reported as standardized mean difference with 95% credible intervals (in parentheses). The comparison between the treatments should be read from left to right. The network meta-analysis results are presented in the left lower (by comparing columns with rows), and the pairwise meta-analysis results are presented in the right upper (by comparing rows with columns). Abbreviations: CS, corticosteroid; AB, autologous blood; BT, botulinum toxin; PRP, platelet-rich plasma; PL, placebo